Safety of hormone replacement therapy in gynaecological cancer survivors

被引:25
作者
Biliatis, I. [1 ]
Thomakos, N. [1 ]
Rodolakis, A. [1 ]
Akrivos, N. [1 ]
Zacharakis, D. [1 ]
Antsaklis, A. [1 ]
机构
[1] Univ Athens, Alexandra Gen Hosp, Dept Obstet & Gynecol 1, Athens 11528, Greece
关键词
Cervical cancer; endometrial cancer; oestrogens; HRT; menopause; ovarian cancer; II ENDOMETRIAL CANCER; ESTROGEN REPLACEMENT; OVARIAN-CANCER; STAGE-I; POSTMENOPAUSAL WOMEN; CERVICAL-CANCER; RISK; BREAST; CARCINOMA; BRCA2;
D O I
10.3109/01443615.2012.668579
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Therapy for endometrial, ovarian and cervical cancer in young women can cause sudden onset of intense menopausal symptoms, such as hot flushes, emotional disorders and sexual dysfunction. In order to overcome these unpleasant and sometimes severe symptoms, hormone replacement therapy (HRT) has proven to be very effective. However, its safety remains controversial. We reviewed English literature and examined whether administration of HRT in this specific population is related with more recurrences and worse prognosis. Current scientific data, comprising mainly retrospective studies, suggest that recurrence rates and survival are comparable between HRT users and non-users. However, large randomised trials are missing and definitive conclusions cannot be drawn. Gynaecological cancer survivors using HRT, although they seem to have little if any risk for recurrence, should be correctly informed about the lack of strong evidence.
引用
收藏
页码:321 / 325
页数:5
相关论文
共 41 条
[1]  
[Anonymous], 2009, SEER Cancer Statistics Review, 1975-2006
[2]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[3]   Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? [J].
Ayhan, A ;
Taskiran, C ;
Simseky, S ;
Severy, A .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (02) :805-808
[4]   Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: A Gynecologic Oncology Group Study [J].
Barakat, RR ;
Bundy, BN ;
Spirtos, NM ;
Bell, J ;
Mannel, RS .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) :587-592
[5]   Ovarian cancer and hormone replacement therapy in the Million Women Study [J].
Beral, Valerie ;
Bull, Diana ;
Green, Jane ;
Reeves, Gillian .
LANCET, 2007, 369 (9574) :1703-1710
[6]  
Berek JS, 2002, NOVAKS GYNECOLOGY, P1280
[7]   Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women [J].
Beresford, SAA ;
Weiss, NS ;
Voigt, LF ;
McKnight, B .
LANCET, 1997, 349 (9050) :458-461
[8]  
Bolton JL, 2001, CHEM RES TOXICOL, V2, P93
[9]   Estrogen replacement in surgical stage I and II endometrial cancer survivors [J].
Chapman, JA ;
DiSaia, PJ ;
Osann, K ;
Roth, PD ;
Gillotte, DL ;
Berman, ML .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (05) :1195-1200
[10]   Influence of estrogen plus progestin on breast, cancer and mammography in healthy postmenopausal women - The Women's Health Initiative Randomized trial [J].
Chlebowski, RT ;
Hendrix, SL ;
Langer, RD ;
Stefanick, ML ;
Gass, M ;
Lane, D ;
Rodabough, RJ ;
Gilligan, MA ;
Cyr, MG ;
Thomson, CA ;
Khandekar, J ;
Petrovitch, H ;
McTiernan, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (24) :3243-3253